• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Gilead Sciences To Rally Around 28%? Here Are 10 Other Analyst Forecasts For Tuesday

    5/16/23 8:24:50 AM ET
    $ABST
    $CLNN
    $DKNG
    $GILD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Services-Misc. Amusement & Recreation
    Consumer Discretionary
    Get the next $ABST alert in real time by email
    • Morgan Stanley raised the price target for DraftKings Inc. (NASDAQ:DKNG) from $23 to $25. Morgan Stanley analyst Stephen Grambling maintained an Overweight rating. DraftKings shares fell 0.2% to close at $23.49 on Monday.
    • Keefe, Bruyette & Woods boosted the price target for Selective Insurance Group, Inc. (NASDAQ:SIGI) from $104 to $106. Keefe, Bruyette & Woods analyst Meyer Shields maintained a Market Perform rating. Selective Insurance shares gained 0.3% to close at $103.02 on Monday.
    • TD Securities cut the price target for Absolute Software Corporation (NASDAQ:ABST) from $16 to $11.5. TD Securities analyst David Kwan downgraded the stock from Buy to Tender. Absolute Software shares fell 0.3% to $11.30 in pre-market trading.
    • Goldman Sachs raised XP Inc. (NASDAQ:XP) price target from $20 to $22. Goldman Sachs analyst Tito Labarta maintained a Buy rating. XP shares fell 0.3% to $15.71 in pre-market trading.
    • UBS cut Lincoln National Corporation (NYSE:LNC) price target from $37 to $21. UBS analyst Brian Meredith maintained a Neutral rating. Lincoln National shares rose 2.1% to $19.99 in pre-market trading.
    • Mizuho raised the price target for Toast, Inc. (NYSE:TOST) from $23 to $25. Mizuho analyst Dan Dolev maintained a Buy rating. Toast shares rose 0.8% to $19.59 in pre-market trading.
    • Truist Securities cut Warner Music Group Corp. (NASDAQ:WMG) price target from $37 to $32. Truist Securities analyst Matthew Thornton maintained a Buy rating. Warner Music shares rose 4.2% to close at $26.34 on Monday.
    • Cantor Fitzgerald slashed Clene Inc. (NASDAQ:CLNN) price target from $5 to $4. Cantor Fitzgerald analyst Charles Duncan maintained a Buy rating. Clene shares rose 3.8% to $0.9150 in pre-market trading.
    • Stifel cut The Mosaic Company (NYSE:MOS) price target from $46 to $42.. Stifel analyst Vincent Anderson maintained a Hold rating. Mosaic shares fell 0.1% to $36.58 in pre-market trading.
    • Mizuho boosted HCA Healthcare, Inc (NYSE:HCA) price target from $298 to $305. Mizuho analyst Ann Hynes maintained a Buy rating. HCA Healthcare shares fell 0.6% to $276.00 in pre-market trading.
    • BMO Capital increased Gilead Sciences, Inc. (NASDAQ:GILD) price target from $90 to $100. BMO Capital analyst Evan Seigerman upgraded the stock from Market Perform to Outperform. Gilead Sciences shares rose 0.3% to close at $78.38 on Monday.

    Check This Out: $1.5M Bet On This Healthcare Stock? Check Out These 3 Penny Stocks Insiders Are Aggressively Buying

    Get the next $ABST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABST
    $CLNN
    $DKNG
    $GILD

    CompanyDatePrice TargetRatingAnalyst
    Gilead Sciences Inc.
    $GILD
    2/20/2026$155.00Equal Weight
    Barclays
    DraftKings Inc.
    $DKNG
    2/17/2026$52.00 → $35.00Buy
    Needham
    Gilead Sciences Inc.
    $GILD
    2/11/2026$140.00 → $170.00Buy
    Needham
    DraftKings Inc.
    $DKNG
    2/6/2026$41.00 → $32.00Outperform
    Bernstein
    Toast Inc.
    $TOST
    2/2/2026$42.00 → $36.00Neutral
    DA Davidson
    Mosaic Company
    $MOS
    2/2/2026$36.00Sector Perform → Sector Outperform
    Scotiabank
    Warner Music Group Corp.
    $WMG
    1/27/2026$38.00Buy
    MoffettNathanson
    XP Inc.
    $XP
    1/20/2026$22.00Buy
    Jefferies
    More analyst ratings

    $ABST
    $CLNN
    $DKNG
    $GILD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-6) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215973, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-8) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/25/2024. Application Category: NDA, Application Number: 215974, Application Classification: Efficacy

    11/26/24 4:36:21 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for SUNLENCA issued to GILEAD SCIENCES INC

    Submission status for GILEAD SCIENCES INC's drug SUNLENCA (SUPPL-9) with active ingredient LENACAPAVIR SODIUM has changed to 'Approval' on 11/13/2024. Application Category: NDA, Application Number: 215973, Application Classification: Manufacturing (CMC)

    11/15/24 4:36:27 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABST
    $CLNN
    $DKNG
    $GILD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lincoln National Corporation's Board of Directors Declares Quarterly Cash Dividend

    Lincoln Financial (NYSE:LNC) announced today that the board of directors of Lincoln National Corporation declared a quarterly cash dividend of $0.45 per share on the corporation's common stock. The dividend on the common stock will be payable May 1, 2026 to shareholders of record at the close of business on April 10, 2026. About Lincoln Financial Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2025, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of December 31, 2025, the company has $349 bil

    2/19/26 4:30:00 PM ET
    $LNC
    Life Insurance
    Finance

    Clene to Present at the Emerging Growth Conference

    SALT LAKE CITY, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (NASDAQ:CLNN) (along with its subsidiaries, "Clene") and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Emerging Growth Conference. Virtual Presentation DetailsDate: February 25, 2026Time of Presentation: 1:45 p.m. ETFormat: Corporate update A webcast of the presentation will be available on the "Events" section of the Clene website. Alternative

    2/19/26 8:30:00 AM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Toast Announces Participation at Morgan Stanley Technology, Media, and Telecom Conference

    Toast (NYSE:TOST), the all-in-one digital technology platform built for hospitality, today announced its management team will present at the Morgan Stanley Technology, Media, and Telecom Conference in San Francisco, CA on Tuesday, March 3, 2026 at 8:30am PST. A webcast of the company presentation will be available on Toast's Investor Relations website at https://investors.toasttab.com/overview/. About Toast Toast (NYSE:TOST) is a cloud-based, all-in-one digital technology platform purpose-built for the entire restaurant community. Toast provides a comprehensive platform of software as a service (SaaS) products and financial technology solutions that give restaurants everything they need

    2/17/26 4:05:00 PM ET
    $TOST
    EDP Services
    Technology

    $ABST
    $CLNN
    $DKNG
    $GILD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Bradbury Erik sold $163,530 worth of shares (7,268 units at $22.50), decreasing direct ownership by 17% to 36,736 units (SEC Form 4)

    4 - DraftKings Inc. (0001883685) (Issuer)

    2/20/26 5:34:04 PM ET
    $DKNG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    SEC Form 4 filed by Director Mclaughlin Vallerie

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:57 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Wilcox Reed N

    4 - Clene Inc. (0001822791) (Issuer)

    2/20/26 4:05:22 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABST
    $CLNN
    $DKNG
    $GILD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Gilead Sciences with a new price target

    Barclays initiated coverage of Gilead Sciences with a rating of Equal Weight and set a new price target of $155.00

    2/20/26 8:24:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Needham reiterated coverage on DraftKings with a new price target

    Needham reiterated coverage of DraftKings with a rating of Buy and set a new price target of $35.00 from $52.00 previously

    2/17/26 7:06:48 AM ET
    $DKNG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Needham reiterated coverage on Gilead Sciences with a new price target

    Needham reiterated coverage of Gilead Sciences with a rating of Buy and set a new price target of $170.00 from $140.00 previously

    2/11/26 7:05:53 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABST
    $CLNN
    $DKNG
    $GILD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sloan Harry bought $2,185,000 worth of shares (100,000 units at $21.85), increasing direct ownership by 40% to 350,219 units (SEC Form 4)

    4 - DraftKings Inc. (0001883685) (Issuer)

    2/18/26 9:16:04 AM ET
    $DKNG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    Director Bacus Lisa R bought $50,886 worth of shares (600 units at $84.81), increasing direct ownership by 10% to 6,778 units (SEC Form 4)

    4 - SELECTIVE INSURANCE GROUP INC (0000230557) (Issuer)

    2/3/26 4:07:24 PM ET
    $SIGI
    Property-Casualty Insurers
    Finance

    Director Matlin David J bought $216,664 worth of shares (33,333 units at $6.50), increasing direct ownership by 7% to 477,824 units (SEC Form 4)

    4 - Clene Inc. (0001822791) (Issuer)

    1/13/26 2:48:54 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABST
    $CLNN
    $DKNG
    $GILD
    SEC Filings

    View All

    SEC Form S-4 filed by Lincoln National Corporation

    S-4 - LINCOLN NATIONAL CORP (0000059558) (Filer)

    2/20/26 4:30:36 PM ET
    $LNC
    Life Insurance
    Finance

    SEC Form 10-K filed by Lincoln National Corporation

    10-K - LINCOLN NATIONAL CORP (0000059558) (Filer)

    2/19/26 5:22:21 PM ET
    $LNC
    Life Insurance
    Finance

    SEC Form 144 filed by DraftKings Inc.

    144 - DraftKings Inc. (0001883685) (Subject)

    2/19/26 4:04:55 PM ET
    $DKNG
    Services-Misc. Amusement & Recreation
    Consumer Discretionary

    $ABST
    $CLNN
    $DKNG
    $GILD
    Financials

    Live finance-specific insights

    View All

    Lincoln National Corporation's Board of Directors Declares Quarterly Cash Dividend

    Lincoln Financial (NYSE:LNC) announced today that the board of directors of Lincoln National Corporation declared a quarterly cash dividend of $0.45 per share on the corporation's common stock. The dividend on the common stock will be payable May 1, 2026 to shareholders of record at the close of business on April 10, 2026. About Lincoln Financial Lincoln Financial helps people confidently plan for their vision of a successful financial future. As of December 31, 2025, approximately 17 million customers trust our guidance and solutions across four core businesses – annuities, life insurance, group protection, and retirement plan services. As of December 31, 2025, the company has $349 bil

    2/19/26 4:30:00 PM ET
    $LNC
    Life Insurance
    Finance

    Gilead to Present New HIV Treatment and Prevention Data at CROI 2026, With a Focus on Expanding Options

    – Pivotal Phase 3 Findings Support the Potential of a Novel Single-Tablet Combination of Bictegravir and Lenacapavir for HIV Treatment – – Latest Data from the PURPOSE Program Further Demonstrates the Safety and Efficacy Profile of Twice-Yearly Lenacapavir for HIV Prevention – Gilead Sciences, Inc. (NASDAQ:GILD) today announced details of new clinical and real-world data from its innovative HIV treatment and prevention portfolio and research pipeline that will be presented at the 33rd Conference on Retroviruses and Opportunistic Infections (CROI 2026) being held from February 22-25 in Denver, Colorado. Focusing on expanding therapeutic options to meet the diverse needs of communities af

    2/17/26 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    XP Inc. Reports Fourth Quarter 2025 Results

    XP Inc. (NASDAQ:XP) ("XP" or the "Company"), a leading tech-enabled platform and a trusted pioneer in providing low-fee financial products and services in Brazil, reported today its financial results for the fourth quarter of 2025. Dear Shareholders, Before reflecting on the year, I would like to thank our clients, investment advisors, employees, and partners for their trust, resilience, and commitment. During a challenging period for the investment industry, our people, culture, and clarity of purpose enabled us to continue advancing. At XP Inc., we have always believed that building an enduring financial institution requires courage in difficult times, disciplined decision-making, and

    2/12/26 4:15:00 PM ET
    $XP
    Investment Bankers/Brokers/Service
    Finance

    $ABST
    $CLNN
    $DKNG
    $GILD
    Leadership Updates

    Live Leadership Updates

    View All

    Community Financial System, Inc. Appoints Brenda M. Hall as New Independent Director

    Community Financial System, Inc. (the "Company") (NYSE:CBU) announced today the appointment of Brenda M. Hall to its Board of Directors (the "Board") as a new independent director, effective as of March 1, 2026. Ms. Hall is the former Executive Vice President and Chief Operating Officer of Standard Lines at Selective Insurance Group, Inc. ("Selective") (NASDAQ:SIGI), where she built a distinguished 24-year career marked by progressive advancement and increasing leadership responsibilities. During her tenure at Selective, Ms. Hall most recently served as Chief Operating Officer from October 2019 until her retirement in January 2026. In this role, she oversaw the company's largest business

    2/11/26 4:15:00 PM ET
    $CBU
    $SIGI
    Major Banks
    Finance
    Property-Casualty Insurers

    Gilead Sciences Appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance

    Gilead Sciences, Inc. (NASDAQ:GILD) announced today that Keeley Wettan will be appointed Executive Vice President, General Counsel, Legal & Compliance effective immediately. She will join the company's senior leadership team and report to Chairman and Chief Executive Officer Daniel O'Day. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251218926462/en/Gilead Sciences appoints Keeley Wettan as Executive Vice President, General Counsel, Legal & Compliance Ms. Wettan has held increasingly senior legal leadership roles within Gilead during her 14-year tenure, most recently as Senior Vice President leading the Global Legal Business Par

    12/18/25 8:30:00 AM ET
    $GILD
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Lincoln Financial Appoints Nilanjan (Neel) Adhya as EVP, Chief AI, Data and Analytics Officer

    Lincoln Financial (NYSE:LNC) today announced the appointment of Nilanjan (Neel) Adhya as Executive Vice President, Chief AI, Data and Analytics Officer (CAIDAO), effective January 9, 2026. In this newly created role, Adhya will advance AI and data as enterprise core capabilities. He will report to Ellen Cooper, Chairman, President and CEO, and will join Lincoln's Senior Management Committee. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204014069/en/Neel Adhya; Source: Lincoln Financial Since 2021, Adhya served as Chief Digital Officer and Global Head of Digital Platforms and Experiences at BlackRock, where he orchestrated cl

    12/4/25 4:15:00 PM ET
    $LNC
    Life Insurance
    Finance

    $ABST
    $CLNN
    $DKNG
    $GILD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Clene Inc.

    SC 13G/A - Clene Inc. (0001822791) (Subject)

    11/14/24 3:32:55 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Clene Inc.

    SC 13G - Clene Inc. (0001822791) (Subject)

    11/14/24 3:26:45 PM ET
    $CLNN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Toast Inc.

    SC 13G - Toast, Inc. (0001650164) (Subject)

    11/14/24 1:22:38 PM ET
    $TOST
    EDP Services
    Technology